Modulation of neuroinflammation and oxidative stress by targeting GPR55 - new approaches in the treatment of psychiatric disorders.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
25 May 2024
25 May 2024
Historique:
received:
15
07
2023
accepted:
15
05
2024
revised:
10
05
2024
medline:
26
5
2024
pubmed:
26
5
2024
entrez:
25
5
2024
Statut:
aheadofprint
Résumé
Pharmacological treatment of psychiatric disorders remains challenging in clinical, pharmacological, and scientific practice. Even if many different substances are established for treating different psychiatric conditions, subgroups of patients show only small or no response to the treatment. The neuroinflammatory hypothesis of the genesis of psychiatric disorders might explain underlying mechanisms in these non-responders. For that reason, recent research focus on neuroinflammatory processes and oxidative stress as possible causes of psychiatric disorders. G-protein coupled receptors (GPCRs) form the biggest superfamily of membrane-bound receptors and are already well known as pharmacological targets in various diseases. The G-protein coupled receptor 55 (GPR55), a receptor considered part of the endocannabinoid system, reveals promising modulation of neuroinflammatory and oxidative processes. Different agonists and antagonists reduce pro-inflammatory cytokine release, enhance the synthesis of anti-inflammatory mediators, and protect cells from oxidative damage. For this reason, GPR55 ligands might be promising compounds in treating subgroups of patients suffering from psychiatric disorders related to neuroinflammation or oxidative stress. New approaches in drug design might lead to new compounds targeting different pathomechanisms of those disorders in just one molecule.
Identifiants
pubmed: 38796643
doi: 10.1038/s41380-024-02614-5
pii: 10.1038/s41380-024-02614-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual Research Review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56:345–65.
pubmed: 25649325
doi: 10.1111/jcpp.12381
Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43:476–93.
pubmed: 24648481
pmcid: 3997379
doi: 10.1093/ije/dyu038
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.
pmcid: 8776563
doi: 10.1016/S2215-0366(21)00395-3
Camacho MB, Anastasio TJ. Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation. Front Pharm. 2017;8:925.
doi: 10.3389/fphar.2017.00925
Schildkraut JJ. The Catecholamine Hypothesis Of Affective Disorders: A Review Of Supporting Evidence. AJP. 1965;122:509–22.
doi: 10.1176/ajp.122.5.509
Woolley DW, Shaw E. A Biochemical And Pharmacological Suggestion About Certain Mental Disorders. Proc Natl Acad Sci USA. 1954;40:228–31.
pubmed: 16589461
pmcid: 527980
doi: 10.1073/pnas.40.4.228
Hersey M, Hashemi P, Reagan LP. Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link? Eur J Neurosci. 202;55:2895–911.
Tan T, Xu Z, Gao C, Shen T, Li L, Chen Z, et al. Influence and interaction of resting state functional magnetic resonance and tryptophan hydroxylase-2 methylation on short-term antidepressant drug response. BMC Psychiatry. 2022;22:218.
pubmed: 35337298
pmcid: 8957120
doi: 10.1186/s12888-022-03860-z
Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol. 2012;92:959–75.
pubmed: 22875882
doi: 10.1189/jlb.0212100
Müller N. COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders. Front Psychiatry. 2019;10:375.
pubmed: 31214060
pmcid: 6555131
doi: 10.3389/fpsyt.2019.00375
Monfared RV, Alhassen W, Truong TM, Gonzales MAM, Vachirakorntong V, Chen S, et al. Transcriptome Profiling of Dysregulated GPCRs Reveals Overlapping Patterns across Psychiatric Disorders and Age-Disease Interactions. Cells. 2021;10:2967.
pubmed: 34831190
pmcid: 8616384
doi: 10.3390/cells10112967
Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Inflamm Psychiatr Disord Ann NY Acad Sci 2019;1437:57–67.
doi: 10.1111/nyas.13712
Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol Psychiatr Sci. 2019;28:333–42.
pubmed: 29098977
doi: 10.1017/S2045796017000579
Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Mult Scler. 2015;21:305–17.
pubmed: 25583845
pmcid: 4429164
doi: 10.1177/1352458514564487
Panara AJ, Yarur AJ, Rieders B, Proksell S, Deshpande AR, Abreu MT, et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharm Ther. 2014;39:802–10.
doi: 10.1111/apt.12669
Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune Diseases and Severe Infections as Risk Factors for Schizophrenia: A 30-Year Population-Based Register Study. AJP. 2011;168:1303–10.
doi: 10.1176/appi.ajp.2011.11030516
Endres D, Leypoldt F, Bechter K, Hasan A, Steiner J, Domschke K, et al. Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. Eur Arch Psychiatry Clin Neurosci. 2020;270:803–18.
pubmed: 32166503
pmcid: 7474714
doi: 10.1007/s00406-020-01113-2
Song H, Fang F, Tomasson G, Arnberg FK, Mataix-Cols D, Fernández de la Cruz L, et al. Association of Stress-Related Disorders With Subsequent Autoimmune Disease. JAMA. 2018;319:2388.
pubmed: 29922828
pmcid: 6583688
doi: 10.1001/jama.2018.7028
Basterzi AD, Aydemir Ç, Kisa C, Aksaray S, Tuzer V, Yazici K, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol Clin Exp. 2005;20:473–6.
doi: 10.1002/hup.717
Gazal M, Souza LD, Fucolo BA, Wiener CD, Silva RA, Pinheiro RT, et al. The impact of cognitive behavioral therapy on IL-6 levels in unmedicated women experiencing the first episode of depression: A pilot study. Psychiatry Res. 2013;209:742–5.
pubmed: 23541242
doi: 10.1016/j.psychres.2013.03.002
Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuro Psychopharmacol Biol Psychiatry. 2009;33:722–6.
doi: 10.1016/j.pnpbp.2009.03.020
Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry. 2019;9:233.
pubmed: 31534116
pmcid: 6751188
doi: 10.1038/s41398-019-0570-y
Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15:384–92.
pubmed: 19488045
doi: 10.1038/mp.2009.47
Kim H-W, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry. 2011;16:419–28.
pubmed: 20038946
doi: 10.1038/mp.2009.137
Ng A, Tam WW, Zhang MW, Ho CS, Husain SF, McIntyre RS, et al. IL-1β, IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer’s disease: Systematic Review and Meta-Analysis. Sci Rep. 2018;8:12050.
pubmed: 30104698
pmcid: 6089986
doi: 10.1038/s41598-018-30487-6
Hopperton KE, Mohammad D, Trépanier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review. Mol Psychiatry. 2018;23:177–98.
pubmed: 29230021
doi: 10.1038/mp.2017.246
Joshi YB, Praticò D. Lipid peroxidation in psychiatric illness: overview of clinical evidence. Oxid Med Cell Longev. 2014;2014:828702.
pubmed: 24868318
pmcid: 4020299
doi: 10.1155/2014/828702
Krivosova M, Gondas E, Murin R, Dohal M, Ondrejka I, Tonhajzerova I, et al. The Plasma Levels of 3-Hydroxybutyrate, Dityrosine, and Other Markers of Oxidative Stress and Energy Metabolism in Major Depressive Disorder. Diagnostics. 2022;12:813.
pubmed: 35453861
pmcid: 9025710
doi: 10.3390/diagnostics12040813
Chandley MJ, Szebeni A, Szebeni K, Wang-Heaton H, Garst J, Stockmeier CA, et al. Markers of elevated oxidative stress in oligodendrocytes captured from the brainstem and occipital cortex in major depressive disorder and suicide. Progr Neuro Psychopharmacol Biol Psychiatry. 2022;117:110559.
Pandolfo G, Genovese G, Bruno A, Campolo D, Tigano V, Cristani M, et al. Advanced glycation end-products and advanced oxidation protein products in schizophrenia. Psychiatry Res. 2022;311:114527.
pubmed: 35344686
doi: 10.1016/j.psychres.2022.114527
Pistis G, Vázquez-Bourgon J, Fournier M, Jenni R, Cleusix M, Papiol S, et al. Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01779-1 .
MacKinley M, Ford SD, Jeon P, Théberge J, Palaniyappan L. Central Oxidative Stress and Early Vocational Outcomes in First Episode Psychosis: A 7-Tesla Magnetic Resonance Spectroscopy Study of Glutathione. Schizophrenia Bull. 2022;48:921–30.
Singh A, Kukreti R, Saso L, Kukreti S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules. 2019;24:1583.
pubmed: 31013638
pmcid: 6514564
doi: 10.3390/molecules24081583
Yin Z, Gao D, Du K, Han C, Liu Y, Wang Y, et al. Rhein Ameliorates Cognitive Impairment in an APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease by Relieving Oxidative Stress through Activating the SIRT1/PGC-1α Pathway. Oxid Med Cell Longev. 2022;2022:2524832.
pubmed: 35360200
pmcid: 8964225
doi: 10.1155/2022/2524832
Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, et al. The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov. 2013;12:25–34.
pubmed: 23237917
doi: 10.1038/nrd3859
Vass M, Kooistra AJ, Yang D, Stevens RC, Wang M-W, de Graaf C. Chemical Diversity in the G Protein-Coupled Receptor Superfamily. Trends Pharmacol Sci. 2018;39:494–512.
pubmed: 29576399
doi: 10.1016/j.tips.2018.02.004
Seyedabadi M, Ghahremani MH, Albert PR. Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential. Pharmacol Therapeutics. 2019;200:148–78.
doi: 10.1016/j.pharmthera.2019.05.006
Catapano LA, Manji HK. G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta. 2007;1768:976–93.
pubmed: 17078926
doi: 10.1016/j.bbamem.2006.09.025
Fatemi I, Abdollahi A, Shamsizadeh A, Allahtavakoli M, Roohbakhsh A. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson’s disease rat model. Acta Neuropsychiatr. 2021;33:15–21.
pubmed: 32967746
doi: 10.1017/neu.2020.30
Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, et al. GPR55: A therapeutic target for Parkinson’s disease? Neuropharmacology. 2017;125:319–32.
pubmed: 28807673
doi: 10.1016/j.neuropharm.2017.08.017
Wróbel A, Serefko A, Szopa A, Ulrich D, Poleszak E, Rechberger T. O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment. Front Pharm. 2020;11:1002.
doi: 10.3389/fphar.2020.01002
Rahimi A, Hajizadeh Moghaddam A, Roohbakhsh A. Central administration of GPR55 receptor agonist and antagonist modulates anxiety-related behaviors in rats. Fundam Clin Pharm. 2015;29:185–90.
doi: 10.1111/fcp.12099
García-Gutiérrez MS, Navarrete F, Navarro G, Reyes-Resina I, Franco R, Lanciego JL, et al. Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims. Neurotherapeutics. 2018;15:796–806.
pubmed: 29435814
pmcid: 6095782
doi: 10.1007/s13311-018-0610-y
Shore DM, Reggio PH. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front Pharm. 2015;6:69.
doi: 10.3389/fphar.2015.00069
Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HHQ, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ΨGPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol Brain Res. 1999;64:193–8.
pubmed: 9931487
doi: 10.1016/S0169-328X(98)00277-0
Marichal-Cancino BA, Fajardo-Valdez A, Ruiz-Contreras AEra, Mendez-Díaz M, Prospero-García O. Advances in the Physiology of GPR55 in the Central Nervous System. CN. 2017;15:771–8.
Morales P, Reggio PH. An Update on Non-CB
pubmed: 29098189
pmcid: 5665501
doi: 10.1089/can.2017.0036
Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci. 2009;30:156–63.
pubmed: 19233486
doi: 10.1016/j.tips.2008.12.004
Arifin S, Falasca M. Lysophosphatidylinositol Signalling and Metabolic Diseases. Metabolites. 2016;6:6.
pubmed: 26784247
pmcid: 4812335
doi: 10.3390/metabo6010006
Falasca M, Ferro R. Role of the lysophosphatidylinositol/GPR55 axis in cancer. Adv Biol Regul. 2016;60:88–93.
pubmed: 26588872
doi: 10.1016/j.jbior.2015.10.003
Fondevila MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, Buque X, Gonzalez-Rodriguez A, et al. The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis. Hepatology. 2021;73:606–24.
pubmed: 32329085
doi: 10.1002/hep.31290
Henstridge CM, Balenga NAB, Kargl J, Andradas C, Brown AJ, Irving A, et al. Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55. Mol Endocrinol. 2011;25:1835–48.
pubmed: 21964594
pmcid: 5417173
doi: 10.1210/me.2011-1197
Ross RA. L-α-Lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci. 2011;32:265–9.
pubmed: 21367464
doi: 10.1016/j.tips.2011.01.005
Mutel V, Bettler B. The pros of not being competitive. Curr Neuropharmacol. 2007;5:148.
pubmed: 19305796
pmcid: 2656814
doi: 10.2174/157015907781695964
Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun. 2007;362:928–34.
pubmed: 17765871
doi: 10.1016/j.bbrc.2007.08.078
Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor: GPR55, a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092–101.
pubmed: 17876302
pmcid: 2095107
doi: 10.1038/sj.bjp.0707460
Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci. 2008;105:2699–704.
pubmed: 18263732
pmcid: 2268199
doi: 10.1073/pnas.0711278105
Apweiler M, Saliba SW, Streyczek J, Hurrle T, Gräßle S, Bräse S, et al. Targeting Oxidative Stress: Novel Coumarin-Based Inverse Agonists of GPR55. IJMS. 2021;22:11665.
pubmed: 34769094
pmcid: 8584154
doi: 10.3390/ijms222111665
Zeng Y, Irvine R, Hiley C. Biased Signalling Might be the Answer to the Inconsistent Pharmacology of GPR55. FASEB J. 2015;29:772–7.
Apweiler M, Streyczek J, Saliba SW, Collado JA, Hurrle T, Gräßle S, et al. Functional Selectivity of Coumarin Derivates Acting via GPR55 in Neuroinflammation. Int J Mol Sci. 2022;23:959.
pubmed: 35055142
pmcid: 8779649
doi: 10.3390/ijms23020959
Ishiguro H, Onaivi ES, Horiuchi Y, Imai K, Komaki G, Ishikawa T, et al. Functional polymorphism in the GPR55 gene is associated with anorexia nervosa. Synapse. 2011;65:103–8.
pubmed: 20506567
doi: 10.1002/syn.20821
Ahmed S, Abir AH, Sharmin O, Khurshid N, Akter A, Nakshy NT, et al. Modulation of PI3K/Akt/GSK3β signaling cascade through G protein-coupled receptor 55 (GPR55) activation: Prenatal lysophosphatidylinositol attenuates valproic acid-induced synaptic abnormalities and mitochondrial dysfunction. Life Sci. 2023;334:122195.
pubmed: 37866808
doi: 10.1016/j.lfs.2023.122195
Liu Q, Yu J, Li X, Guo Y, Sun T, Luo L, et al. Cannabinoid receptor GPR55 activation blocks nicotine use disorder by regulation of AMPAR phosphorylation. Psychopharmacology. 2021;238:3335–46.
pubmed: 34648060
doi: 10.1007/s00213-021-05949-x
He Y, Shen H, Bi G-H, Zhang H-Y, Soler-Cedeño O, Alton H, et al. GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice. Transl Psychiatry. 2024;14:101.
O’Callaghan JP, Sriram K, Miller DB. Defining “Neuroinflammation”. Ann N Y Acad Sci. 2008;1139:318–30.
pubmed: 18991877
doi: 10.1196/annals.1432.032
Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: a potential therapeutic target. Expert Opin Therapeutic Targets. 2005;9:887–900.
doi: 10.1517/14728222.9.5.887
DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139:136–53.
pubmed: 26990767
pmcid: 5025335
doi: 10.1111/jnc.13607
Hill JD, Zuluaga-Ramirez V, Gajghate S, Winfield M, Sriram U, Rom S, et al. Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation. Brain Behav Immun. 2019;76:165–81.
pubmed: 30465881
doi: 10.1016/j.bbi.2018.11.017
Minamihata T, Takano K, Moriyama M, Nakamura Y. Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia. Inflammation. 2020;43:1971–87.
pubmed: 32519268
doi: 10.1007/s10753-020-01271-4
Shen S-Y, Yu R, Li W, Liang L-F, Han Q-Q, Huang H-J, et al. The neuroprotective effects of GPR55 against hippocampal neuroinflammation and impaired adult neurogenesis in CSDS mice. Neurobiol Dis. 2022;169:105743.
pubmed: 35490927
doi: 10.1016/j.nbd.2022.105743
Saliba SW, Jauch H, Gargouri B, Keil A, Hurrle T, Volz N, et al. Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells. J Neuroinflammation. 2018;15:322.
pubmed: 30453998
pmcid: 6240959
doi: 10.1186/s12974-018-1362-7
Malek N, Popiolek-Barczyk K, Mika J, Przewlocka B, Starowicz K. Anandamide, Acting via Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plasticity. 2015;2015:1–10.
doi: 10.1155/2015/130639
Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg’s. Arch Pharmacol. 2002;366:381–416.
doi: 10.1007/s00210-002-0588-0
Berg KA, Clarke WP. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. Int J Neuropsychopharmacol. 2018;21:962–77.
pubmed: 30085126
pmcid: 6165953
doi: 10.1093/ijnp/pyy071
Wisler JW, Xiao K, Thomsen AR, Lefkowitz RJ. Recent developments in biased agonism. Curr Opin Cell Biol. 2014;27:18–24.
pubmed: 24680426
doi: 10.1016/j.ceb.2013.10.008
Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013;12:205–16.
pubmed: 23411724
doi: 10.1038/nrd3954
Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu H-M, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis. 2011;17:1651–64.
pubmed: 21744421
doi: 10.1002/ibd.21538
Stančić A, Jandl K, Hasenöhrl C, Reichmann F, Marsche G, Schuligoi R, et al. The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterol Motil. 2015;27:1432–45.
pubmed: 26227635
pmcid: 4587547
doi: 10.1111/nmo.12639
Saliba SW, Gläser F, Deckers A, Keil A, Hurrle T, Apweiler M, et al. Effects of a Novel GPR55 Antagonist on the Arachidonic Acid Cascade in LPS-Activated Primary Microglial Cells. IJMS. 2021;22:2503.
pubmed: 33801492
pmcid: 7958845
doi: 10.3390/ijms22052503
Shi Q, Yang L, Shi W, Wang L, Zhou S, Guan S, et al. The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress. Mol Brain. 2017;10:38.
pubmed: 28800762
pmcid: 5553743
doi: 10.1186/s13041-017-0318-7
Dyck GJB, Maayah ZH, Eurich DT, Dyck JRB. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review. Schizophrenia Bull Open. 2022;3:sgab053.
doi: 10.1093/schizbullopen/sgab053
Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology. 2021;238:9–28.
pubmed: 33221931
doi: 10.1007/s00213-020-05712-8
Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry. 2016;21:1009–26.
pubmed: 27271499
pmcid: 4960446
doi: 10.1038/mp.2016.90
Xiang X, Wang X, Jin S, Hu J, Wu Y, Li Y, et al. Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer’s disease induced by Aβ1–42 through inhibiting RhoA/ROCK2 pathway. Prog Neuro Psychopharmacol Biol Psychiatry. 2022;112:110423.
doi: 10.1016/j.pnpbp.2021.110423
Xiang X, Wang X, Wu Y, Hu J, Li Y, Jin S, et al. Activation of GPR55 attenuates cognitive impairment, oxidative stress, neuroinflammation, and synaptic dysfunction in a streptozotocin-induced Alzheimer’s mouse model. Pharmacol Biochem Behav. 2022;214:173340.
pubmed: 35090841
doi: 10.1016/j.pbb.2022.173340
Wang X, Xiang XT, Hu J, Wu YM, Li Y, Jin SY, et al. Pharmacological activation of GPR55 improved cognitive impairment, neuroinflammation, oxidative stress and apoptosis induced by lipopolysaccharide in mice. J Mol Neurosci. 2022;72:1656–69.
Medina-Vera D, Rosell-Valle C, López-Gambero AJ, Navarro JA, Zambrana-Infantes EN, Rivera P, et al. Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity. Biology. 2020;9:377.
pubmed: 33167441
pmcid: 7694492
doi: 10.3390/biology9110377
Martínez-Pinilla E, Aguinaga D, Navarro G, Rico AJ, Oyarzábal J, Sánchez-Arias JA, et al. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease. Mol Neurobiol. 2019;56:5900–10.
pubmed: 30687889
doi: 10.1007/s12035-019-1495-4
Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration. FEBS Lett. 2018;592:692–702.
pubmed: 29292494
doi: 10.1002/1873-3468.12964
Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive Oxygen Species in Metabolic and Inflammatory Signaling. Circ Res. 2018;122:877–902.
pubmed: 29700084
pmcid: 5926825
doi: 10.1161/CIRCRESAHA.117.311401
Nayernia Z, Jaquet V, Krause K-H. New Insights on NOX Enzymes in the Central Nervous System. Antioxid Redox Signal. 2014;20:2815–37.
pubmed: 24206089
pmcid: 4026375
doi: 10.1089/ars.2013.5703
Laurindo FRM, Araujo TLS, Abrahão TB. Nox NADPH Oxidases and the Endoplasmic Reticulum. Antioxid Redox Signal. 2014;20:2755–75.
pubmed: 24386930
pmcid: 4026305
doi: 10.1089/ars.2013.5605
Wang L, Chen Y, Sternberg P, Cai J. Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE. Invest Ophthalmol Vis Sci. 2008;49:1671–8.
pubmed: 18385090
doi: 10.1167/iovs.07-1099
Chen Y, Feng X, Hu X, Sha J, Li B, Zhang H, et al. Dexmedetomidine Ameliorates Acute Stress-Induced Kidney Injury by Attenuating Oxidative Stress and Apoptosis through Inhibition of the ROS/JNK Signaling Pathway. Oxid Med Cell Longev. 2018;2018:1–12.
Huang L, Ramirez JC, Frampton GA, Golden LE, Quinn MA, Pae HY, et al. Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest. 2011;91:1007–17.
pubmed: 21464819
pmcid: 3126905
doi: 10.1038/labinvest.2011.62
Wang Z, Liu B, Zhu J, Wang D, Wang Y. Nicotine-mediated autophagy of vascular smooth muscle cell accelerates atherosclerosis via nAChRs/ROS/NF-κB signaling pathway. Atherosclerosis. 2019;284:1–10.
pubmed: 30856513
doi: 10.1016/j.atherosclerosis.2019.02.008
Akimov MG, Gamisonia AM, Dudina PV, Gretskaya NM, Gaydaryova AA, Kuznetsov AS, et al. GPR55 Receptor Activation by the N-Acyl Dopamine Family Lipids Induces Apoptosis in Cancer Cells via the Nitric Oxide Synthase (nNOS) Over-Stimulation. IJMS. 2021;22:622.
pubmed: 33435517
pmcid: 7826688
doi: 10.3390/ijms22020622
Kobayashi M, Yamamoto M. Molecular Mechanisms Activating the Nrf2-Keap1 Pathway of Antioxidant Gene Regulation. Antioxid Redox Signal. 2005;7:385–94.
pubmed: 15706085
doi: 10.1089/ars.2005.7.385
Singh NS, Bernier M, Wainer IW. Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacol Res. 2016;111:757–66.
pubmed: 27423937
pmcid: 5026616
doi: 10.1016/j.phrs.2016.07.013
Zeng Y, Liu Z, Tan X, Lei L. The GPR55 antagonist CID16020046 mitigates advanced glycation end products (AGEs)- induced chondrocyte activation. Chem Biol Interact. 2020;325:109088.
pubmed: 32360554
doi: 10.1016/j.cbi.2020.109088
Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ. 2022;378:e067606.
Entsuah AR, Huang H, Thase ME. Response and Remission Rates in Different Subpopulations With Major Depressive Disorder Administered Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Placebo. J Clin Psychiatry. 2001;62:869–77.
pubmed: 11775046
doi: 10.4088/JCP.v62n1106
Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, et al. Time to Treatment Response in First-Episode Schizophrenia: Should Acute Treatment Trials Last Several Months? J Clin Psychiatry. 2011;72:1691–6.
pubmed: 21939612
pmcid: 3246541
doi: 10.4088/JCP.10m06349
Streyczek J, Apweiler M, Sun L, Fiebich BL. Turmeric Extract (Curcuma longa) Mediates Anti-Oxidative Effects by Reduction of Nitric Oxide, iNOS Protein-, and mRNA-Synthesis in BV2 Microglial Cells. Molecules. 2022;27:784.
pubmed: 35164047
pmcid: 8840760
doi: 10.3390/molecules27030784
Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395:203–30.
pubmed: 24127541
doi: 10.1515/hsz-2013-0241
Paniagua L, Diaz-Cueto L, Huerta-Reyes M, Arechavaleta-Velasco F. Cadmium exposure induces interleukin-6 production via ROS-dependent activation of the ERK1/2 but independent of JNK signaling pathway in human placental JEG-3 trophoblast cells. Reprod Toxicol. 2019;89:28–34.
pubmed: 31252067
doi: 10.1016/j.reprotox.2019.06.008
Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 2015;88:108–46.
pubmed: 26122708
pmcid: 4659505
doi: 10.1016/j.freeradbiomed.2015.06.021
Abraham K, Wöhrlin F, Lindtner O, Heinemeyer G, Lampen A. Toxicology and risk assessment of coumarin: Focus on human data. Mol Nutr Food Res. 2010;54:228–39.
pubmed: 20024932
doi: 10.1002/mnfr.200900281
Alshibl HM, Al-Abdullah ES, Alkahtani HM. Coumarin: A Promising Scaffold for Design and Development of Bioactive Agents. CBC. 2020;16:837–52.
doi: 10.2174/1573407215666190524101510
Hanley JP. Warfarin reversal. J Clin Pathol. 2004;57:1132–9.
pubmed: 15509671
pmcid: 1770479
doi: 10.1136/jcp.2003.008904
Sandhu S, Bansal Y, Silakari O, Bansal G. Coumarin hybrids as novel therapeutic agents. Bioorg Med Chem. 2014;22:3806–14.
pubmed: 24934993
doi: 10.1016/j.bmc.2014.05.032
Rempel V, Volz N, Hinz S, Karcz T, Meliciani I, Nieger M, et al. 7-Alkyl-3-benzylcoumarins: A Versatile Scaffold for the Development of Potent and Selective Cannabinoid Receptor Agonists and Antagonists. J Med Chem. 2012;55:7967–77.
pubmed: 22916707
doi: 10.1021/jm3008213
Rempel V, Volz N, Gläser F, Nieger M, Bräse S, Müller CE. Antagonists for the Orphan G-Protein-Coupled Receptor GPR55 Based on a Coumarin Scaffold. J Med Chem. 2013;56:4798–810.
pubmed: 23679955
doi: 10.1021/jm4005175
Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013;6:41–7.
pubmed: 23272792
doi: 10.1586/ecp.12.74
Ekström F, Gottinger A, Forsgren N, Catto M, Iacovino LG, Pisani L, et al. Dual Reversible Coumarin Inhibitors Mutually Bound to Monoamine Oxidase B and Acetylcholinesterase Crystal Structures. ACS Med Chem Lett. 2022;13:499–506.
pubmed: 35300078
doi: 10.1021/acsmedchemlett.2c00001
Balenga NAB, Aflaki E, Kargl J, Platzer W, Schröder R, Blättermann S, et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 2011;21:1452–69.
pubmed: 21467997
pmcid: 3132458
doi: 10.1038/cr.2011.60
Wang Y, Pan W, Wang Y, Yin Y. The GPR55 antagonist CID16020046 protects against ox-LDL-induced inflammation in human aortic endothelial cells (HAECs). Arch Biochem Biophys. 2020;681:108254.
pubmed: 31904362
doi: 10.1016/j.abb.2020.108254